Alzheimer’s Brain Treatment Shows Promise
- With Alzheimer's disease affecting an estimated seven million Americans, a team at the University of California, Irvine, has unveiled a potential new approach to combat the debilitating illness.
- The experimental therapy leverages stem cells to reprogram microglia, a type of immune cell in the brain, to fight dementia, according to a university press release.
- Researchers used CRISPR gene editing to modify microglia, enabling them to produce an enzyme called neprilysin.This enzyme is known to break down the toxic beta-amyloid plaques that accumulate...
Stem Cell Therapy Shows Promise in Targeting Alzheimer’s Brain Plaques
Table of Contents
With Alzheimer’s disease affecting an estimated seven million Americans, a team at the University of California, Irvine, has unveiled a potential new approach to combat the debilitating illness.
The experimental therapy leverages stem cells to reprogram microglia, a type of immune cell in the brain, to fight dementia, according to a university press release. Microglia serve as the brain’s primary defense against infection and injury.
CRISPR Technology Used to Modify Immune Cells
Researchers used CRISPR gene editing to modify microglia, enabling them to produce an enzyme called neprilysin.This enzyme is known to break down the toxic beta-amyloid plaques that accumulate in the brains of Alzheimer’s patients.
Study Shows Positive Results in Mice
In studies involving mice, the modified cells were observed to protect neurons, reduce inflammation, decrease beta-amyloid accumulation, and reverse neurodegeneration.
The findings were published in the journal Cell Stem Cell. The research was supported by the National Institutes of Health, the California Regenerative Medicine Institute, and the Alzheimer’s Healing Fund.
Targeted Approach Coudl overcome Drug Delivery Challenges
Mathew Blurton-Jones, a professor of neurobiology and behavior and co-author of the study, noted the difficulty of delivering biological products to the brain due to the blood-brain barrier.
“We have developed a programmable and living administration system that raffles that problem residing in the brain itself and responding only when and where it is needed,” Blurton-Jones said.
The researchers emphasized that the programmed cells specifically target amyloid plaques, making this a highly selective treatment strategy.
Further Research Needed
an Alzheimer’s Association representative stated that further research is necessary to fully understand how this drug administration method could impact individuals with or at risk of developing Alzheimer’s.
The representative added that while the work was conducted using animal models, clinical trials in humans are crucial to assess the therapeutic potential of this drug administration mechanism.
stem Cell Therapy Shows Promise in Targeting Alzheimer’s Brain Plaques
Q: What is alzheimer’s disease, and how prevalent is it?
Alzheimer’s disease is a debilitating illness affecting millions of people. According to the University of California, Irvine, approximately seven million Americans are currently affected.
Q: What innovative approach is being explored to combat Alzheimer’s disease?
A team at the University of California, Irvine, has developed a new experimental therapy. This approach utilizes stem cells to reprogram microglia, a type of immune cell within the brain.
Q: What is the role of microglia in the brain?
Microglia are the brain’s primary line of defense. They act as immune cells, protecting the brain against infection and injury.
Q: How are researchers modifying microglia in this new therapy?
Researchers are using CRISPR gene editing technology to modify microglia. This modification enables the microglia to produce an enzyme called neprilysin.
Q: What is the function of neprilysin?
Neprilysin is an enzyme that breaks down the toxic beta-amyloid plaques that accumulate in the brains of Alzheimer’s patients.
Q: What results where observed in studies involving mice?
studies in mice showed positive results. The modified cells:
Protected neurons.
Reduced inflammation.
Decreased beta-amyloid accumulation.
Reversed neurodegeneration.
Q: Where were these findings published?
The findings were published in the journal Cell Stem Cell.
Q: What organizations supported the research?
the research was supported by the National Institutes of Health, the California Regenerative Medicine Institute, and the Alzheimer’s Healing Fund.
Q: What is the challenge of delivering biological products to the brain?
Delivering biological products to the brain is difficult due to the blood-brain barrier.
Q: How does this new approach address the challenge of the blood-brain barrier?
This therapy uses a “programmable and living administration system” that resides in the brain itself, responding only when and where it is needed.
Q: What makes this a targeted treatment strategy?
The programmed cells specifically target amyloid plaques, which makes this a highly selective treatment strategy.
Q: What is the next step in this research?
Further research is needed to fully understand how this drug administration method could impact individuals with or at risk of developing Alzheimer’s. Clinical trials in humans are also crucial.
**Q: What is the key difference between the experimental and standard approaches to Alzheimer’